CD47 and neoplasm: In more aggressive and poorly immunogenic tumors, additional treatment modalities may be necessary to improve tumor control and eradication, such as triple combinations with tumor antigen specific antibodies, CD47/SIRPα antagonists, ICIs, vaccines, or chemotherapy [49, 55].